Image source: Gettty Images.
After Pacira Pharmaceuticals (NASDAQ: PCRX)issued preliminary results for the fourth quarter, its shares jumped 17.3% today.
Pacira Pharmaceuticals markets the surgical pain medicine Exparel, and growing demand for it helped the company produce $72.9 million in revenue during the fourth quarter, according to preliminary results.Exparel sales grew 6.3% year over year, to $71.4 million, bringing full-year 2016 sales to $265.8 million, up 10.8% from 2015. Overall, Pacira Pharmaceuticals' revenue is expected to total$276.4 million, up 11% from 2015.
"2016 was a year of solid execution that has set the stage for continued growth of EXPAREL," saidDave Stack, chief executive officer and chairman of Pacira. "We made important progress advancing our three-part growth strategy that focuses on expanding awareness around opioid-sparing solutions, generating robust clinical data, and forming strategic partnerships."
Stack was mum, however, on how much of those sales made it to the bottom line. Analysts are targeting earnings per share of $0.02 for Q4, and $0.54 for the full year.
The company hopes to continue to expand Exparel's use as an alternative to opioids. In 2017, it expects to provide results from a phase 4 trial in knee and spine surgery, and results from a phase 3 trial evaluating Exparel's use as a nerve block. Additionally, management plans to begin phase 4 trials in soft tissue procedures that could eventually increase Exparel's addressable market, too.
Because the market for opioids is worth billions, and there's significant momentum to shift away from opioid treatments, there could be an opportunity for Exparel to capture additional market share in 2017. For context, roughly 300 million prescriptions were written for pain medicines in 2015, representing $24 billion in sales. Given this company's opportunity to expand Exparel's sales, it's unsurprising that investors cheered today's results.
10 stocks we like better than Pacira Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pacira Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 4, 2017
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him onTwitter where he goes by the handle@ebcapitalto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.